Natera CEO Says Company Is 'Clearly on a Roll' After Record Test Volumes, Raises Outlook

Natera Inc. (NASDAQ: NTRA ) stock surged Friday after the genetic testing company reported second-quarter results that topped Wall Street estimates and raised its full-year revenue outlook, supported by strong oncology demand and continued momentum across its Women’s Health and Organ Health businesses. The company reported a second-quarter loss of 47 cents per share, beating the consensus estimate for a loss of 51 cents per share. Revenue increased 37.7% year over year to $752.8 million, exceeding the analyst consensus estimate of $660.7 million. The growth was driven by higher test volumes and improved average selling prices. Oncology Growth Drives Record Quarter CEO Steve Chapman said the company processed more than 1 million tests for the second consecutive quarter and delivered record oncology volume growth. Natera processed approximately 1.04 million tests during the quarte...